3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Sarcoma
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
55
Specimen Handling
50
Magnetic Resonance Spectroscopy
49
Doxorubicin
44
pembrolizumab
43
Radiotherapy
42
Temozolomide
38
Biopsy
34
Radiation
29
Nivolumab
28
fludarabine
23
Vincristine
22
Irinotecan
21
Gemcitabine
21
X-Rays
20
Ifosfamide
20
Surgical Procedures, Operative
19
atezolizumab
17
cabozantinib
15
Ipilimumab
15
olaparib
13
Sunitinib
13
Paclitaxel
13
Etoposide
13
Blood Specimen Collection
13
regorafenib
12
fludarabine phosphate
12
Phantoms, Imaging
12
Imatinib Mesylate
12
liposomal doxorubicin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
SGN-LIV1A
×
Sarcoma
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled